SEC Form 4 · accession 0001104659-16-090656
Adaptimmune Therapeutics PLC · ADAP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Helen Katrina Tayton-Martin
Officer — Chief Operating Officer
Period of report
Jan 18, 2016
Accepted (ET)
Jan 20, 2016 · 4:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621227
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to purchase Ordinary SharesF1,F2 | $1.2717 | Jan 18, 2016 | A | 939,948 | A | — | Jan 18, 2026 | Ordinary Shares | 939,948 | 939,948 | D |
Explanation of responses
- F1The exercise price was converted from GBP0.89 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the business day prior to the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.
- F2Exercisable as to 234,987 Ordinary Shares on January 18, 2017 and will be exercisable as to the remainder in monthly installments of 19,582 Ordinary Shares on the eighteenth of each month from February 18, 2017 through December 18, 2019, and in one installment of 19,591 Ordinary Shares on January 18, 2020.